A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will compare the effect of A4I antagonist and placebo on MRI lesions,on clinical
endpoints, and safety in patients with relapsing Multiple Sclerosis (MS). Eligible patients
will be randomized to receive placebo or A4I antagonist, 20mg, 80mg or 300mg, po bid.
Patients will undergo MRI brain scans and MS clinical evaluations at intervals throughout the
study. The anticipated time on study treatment is 3-12 months, and the target sample size is
100-500 individuals.